Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 11

Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016

Pages
957–963
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Accordingly, HDV RNA detection rates of participant laboratories were71-100% in 2015 and 50-100% in 2016.Conclusion: This study was the first national external quality control program in Turkey regarding HCV RNA genotyping and HDV RNA inthe field of molecular microbiology, and it was implemented successfully.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: To evaluate the HCV RNA genotyping and HDV RNA tests that are performed in molecular microbiology laboratoriesin Turkey as part of a national external quality assessment programme, MOTAKK (Moleküler Tanıda Kalite Kontrol) (English translation:Quality control in molecular diagnostics).Materials and Methods: Plasmas having different HCV RNA genotypes were used to prepare HCV genotype control sera.
📊
Key Findings & Data:The HDV RNAmain stock was prepared from patients with chronic delta hepatitis who had a significant amount of viral load detected, as per the WHOreference materials on viral load studies that were compiled for the purpose of developing HDV RNA control sera.
💡
Conclusion & Impact:Accordingly, HDV RNA detection rates of participant laboratories were71-100% in 2015 and 50-100% in 2016.Conclusion: This study was the first national external quality control program in Turkey regarding HCV RNA genotyping and HDV RNA inthe field of molecular microbiology, and it was implemented successfully.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

Background/Aims: To evaluate the HCV RNA genotyping and HDV RNA tests that are performed in molecular microbiology laboratoriesin Turkey as part of a national external quality assessment programme, MOTAKK (Moleküler Tanıda Kalite Kontrol) (English translation:Quality control in molecular diagnostics).Materials and Methods: Plasmas having different HCV RNA genotypes were used to prepare HCV genotype control sera. The HDV RNAmain stock was prepared from patients with chronic delta hepatitis who had a significant amount of viral load detected, as per the WHOreference materials on viral load studies that were compiled for the purpose of developing HDV RNA control sera. Samples with differentviral loads were prepared from this main stock by dilution. The prepared controls were delivered to the registered laboratories. The laboratories carried out the relevant tests and entered their results via the MOTAKK web page. External quality assessment (EQA) reports ofthe participants were uploaded to the website as well.Results: In total, there were 23 participating laboratories, out of which 20 exclusively performed HCV genotyping, and 15 and 16 onlyperformed HDV RNA in 2015 and 2016, respectively. The success rate of the results of the HCV genotype was 56-96% in 2015 and30-95% in 2016. The tube with a 30% success rate had a recombinant type of HCV, therefore, it could not be detected in most of thelaboratories. The HDV RNA results were evaluated qualitatively. Accordingly, HDV RNA detection rates of participant laboratories were71-100% in 2015 and 50-100% in 2016.Conclusion: This study was the first national external quality control program in Turkey regarding HCV RNA genotyping and HDV RNA inthe field of molecular microbiology, and it was implemented successfully.

🔖

Cite This Article

KARATAYLI, E., SOYDEMİR, E., AKSOY, Z. B., KIZILPINAR, M., KOÇAK, A. A., KARATAYLI, S. C., YURDCU, E., YILDIRIM, U., GÜRİZ, H., BOZDAYI, G., YURDAYDIN, C., İLHAN, O., YILDIRIM, Y., Group, M. H. G. A. H. S., BOZDAYI, A. M. (2019). Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 11, 957–963. https://ajindex.com/articles/408808

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017
  2. [CrossRef] 2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015
  3. [CrossRef] 3. Ippolito G, Capobianchi MR, Lanini S, Antonelli G. Is hepatitis C virus eradication around the corner only 25 years after its discovery? Int J Antimicrob Agents 2015
  4. [CrossRef] 4. Rodriguez C, Soulier A, Demontant V, et al. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination. Scientific Reports 2018
  5. [CrossRef] 5. Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2018
  6. [CrossRef] 6. Abacioglu YH, Davidson F, Tuncer S, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995
  7. [CrossRef] 7. Kabakci Alagöz G, Karatayli SC, Karatayli E, et al. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5UTR regions in genotyping efficiency. Turk J Gastroenterol 2014
  8. [CrossRef] 8. Nemoz B, Roger L, Leroy V, Poveda J-D, Morand P, Larrat S. Evaluation of the cobas®GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures. PLoS ONE 2018
  9. e0194396. [CrossRef] 9. Zein NN. Clinical Significance of Hepatitis C Genotypes. Clin Microbiol Rev 2000
  10. [CrossRef] 10. Idilman R, Cinar K, Seven G, et al. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepatit 2012
  11. [CrossRef] 11. Noureddin M, Gish R. Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years after Discovery. Curr Gastroenterol Rep 2014
  12. [CrossRef] 12. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int 2011
  13. [CrossRef] 13. Le Gal F, Brichler S, Sahli R, Chevret S, Gordien E. First International External Quality Assessment for Hepatitis Delta Virus RNA Quantification in Plasma. Hepatology 2016
  14. [CrossRef] 14. Rizzetto M. The